First CAR T-Cell Therapy Approved in U.S.

The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

By Shawna Williams | August 30, 2017

Each patient’s T-cells will be harvested from the body and genetically programmed to target leukemia cells. ALLINONEMOVIE, PIXABAYThe US Food and Drug Administration (FDA) announced today (August 30) that it has approved the first therapy involving chimeric antigen receptor (CAR) T cells for clinical use. Each dose of Novartis’s drug, Kymriah, will consist of a patient’s own white blood cells, harvested from the body and genetically programmed to seek an antigen on the surface of leukemia cells.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” says FDA Commissioner Scott Gottlieb in a statement. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

Kymriah is approved for patients 25 years old and younger who have B-cell acute lymphoblastic leukemia, and whose disease has relapsed at least twice or is still detectable after other treatment. In a clinical trial, the therapy left 83 percent of such patients cancer-free after three months. STAT notes that only a few hundred patients per year may be eligible for the cell therapy. Priced at $475,000, it will be offered at just 32 sites around the country.

See “The CAR T-Cell Race

Despite the limited use of Kymriah, the approval ushers in “a new approach to the treatment of cancer and other serious and life-threatening diseases,” FDA says. Business Insider reports that at an FDA meeting last month, oncologist Tim Cripe of Nationwide Children’s Hospital called Kymriah “the most exciting thing I’ve seen in my lifetime.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: Interested


Posts: 8

August 31, 2017

Science forges ahead in the age of proactive medicine with laudable intent.  But as I enthusiastically read all the new developments for treatment and detection of cancer, neurological disorders, and so forth I have to be curious about the market price for some of these treatments/cures.  I have called re: Glioma treatment with lytic virology, Crohn's with MAB therapy and a few others and requested pricing without insurance.  "Assistance is available" is the usual and somewhat disheartening answer. The one time pricing for this particular treatment is $475,000 with caveats to include timed success, possible post treatment, etc. As I suspect that cost is not insulated by 3rd parties (insurance) the price is almost laughable. 

Popular Now

  1. Salk Institute Suspends Cancer Scientist Inder Verma
  2. Long-Term Study Reveals Flip in Plant Responses to Carbon Dioxide
  3. Jim Bridenstine Confirmed to Lead NASA
  4. RNA Injection Restores Hearing in Guinea Pigs